Salute e Benessere

Softgels Dietary Supplements Market to Surpass USD 358.6 Billion by 2032, Driven…

Growth Drivers: Preventive Health and Technological Advancements Growth Drivers: Preventive Health and Technological Advancements The global dietary supplement industry is being reshaped by measurable trends that directly influence softgel consumption patterns: Download PDF Brochure:https://www.datamintelligence.com/download-sample/softgels-dietary-supplements-market Browse in-depth TOC on "Softgels Dietary Supplements Market"70 – Tables 66 – Figures 195 – Pages ...

GHA Awards Top Honor to VitalLife: "Certified with Distinction" Recognizes…

"Receiving 'Certified with Distinction' from GHA is a testament to the dedication of our clinicians, care teams and partners to deliver world-class, evidence-driven care for international patients," said Asst.Prof.Dr. Polakit Teekakirikul, CEO of VitalLife Scientific Wellness Center. "Our mission is to combine scientific based wellness programs with a hospitality-minded patient experience. This recognition both validates our approach and reinforces our commitment to continuously…

24 million new wishes added in just one month to GoWish shows what we want under…

"Users of GoWish have started creating their Christmas wish lists earlier this year, giving us a clear picture of what's topping the lists - and what might be a good idea to put under the tree for loved ones this Christmas", says Casper Ravn-Sørensen, Chief Growth Officer at GoWish, noting that the GoWish-app on Nov 3 was the 2nd most downloaded on the US App Store. "Users of GoWish have started creating their Christmas wish lists earlier this year, giving us a clear picture of…

From Pandemic Innovation to Global Collaboration: Taiwan's TCM Shines at CPHI…

The Pavilion was also invited to appear on the CPHI Newsbeat Stage— the first time a Taiwanese exhibitor has ever been selected for this global media platform. During the session, it delivered a brief announcement on Taiwan's evidence-based TCM development, followed by an interview with Raman Sehgal, host of the Molecule to Market podcast, with around 10 media outlets in attendance. The exposure further elevated Taiwan's international visibility at the event. The Pavilion was also invited to...

Invitation to presentation of BioArctic's third quarter report for July -…

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:https://bioarctic.events.inderes.com/q3-report-2025/register If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to...

NCCN Celebrates Expanding Access to Cancer Treatment in Africa at 2025 AORTIC…

The NCCN Global Program has been working with the American Cancer Society, the African Cancer Coalition, and other groups since 2017. That year, the organizations jointly announced the launch of NCCN Harmonized Guidelines™ for Sub-Saharan Africa driven by the leadership of the African Cancer Coalition. Those resources—based on the trusted NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that cancer care providers worldwide rely on—used color-coding to represent both the optimal…

Elevaris Introduces CDMO Services, Procedural Needle Portfolio to EMEA

"Elevaris Medical Devices brought together two long-trusted companies with highly complementary capabilities," said Richard Zrebiec, CEO of Elevaris Medical Devices, "and we're thrilled to introduce these offerings on Europe's largest stage for medical device manufacturers. "Elevaris Medical Devices brought together two long-trusted companies with highly complementary capabilities," saidRichard Zrebiec, CEO of Elevaris Medical Devices, "and we're thrilled to…

Zelluna ASA: Disclosure of large shareholding

In accordance with the Norwegian Securities Trading Act Section 4-3, Inven2 AS ( “Inven2” ) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 10% threshold following the share capital increase in Zelluna through the private placement on November 3 rd2025. Previous shareholding : 10,79% New shareholding : 9,01% Total number of shares held: 2,207,034The reduction in ownership is due to dilution as result of the private placement. Inven2 has not...

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, November 4, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...

Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25

Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25FY 2024/25 organic growth of 7% and EBIT margin 1of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%. • EBIT 1,2was DKK 7,670 million, a 5% increase from last year. The EBIT margin 1,2was 28%, against 27% last year. • Adjusted 3net...

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved…

Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroids Pratteln, Switzerland, November 4, 2025– Santhera Pharmaceuticals (SIX: SANN) today...

Coloplast A/S - Full-Year Financial Results 2024/25

2024/25 Full year financial results1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin 1of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%. • Growth in Ostomy Care was broad based with good contribution from recent...

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the "Retail Offering"). Radforsk…

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate…

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trialshowcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patientsLp(a)...

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in Europe exceeded the threshold triggering a USD 30 million sales milestone payment...

Zelluna ASA – Ex. date

The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025.This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika…

Immune response successfully improved with second generation vaccine candidateSaint-Herblain (France), November 4, 2025 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). The randomized controlled Phase 1 trial, VLA1601-102, enrolled approximately...

Philips continues momentum; delivers strong order intake, step-up in sales…

November 4, 2025Q3 2025 Group HighlightsComparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the rangeRoy Jakobs, CEO of Royal...

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved…

Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroids Pratteln, Switzerland, November 4, 2025– Santhera Pharmaceuticals (SIX: SANN) today reported positive topline results from an analysis...

ICP DAS-BMP Redefines Medical Material Performance with Low-Migration and…

The low-migration Arothane™ ARP-B20 TPU is ISO 10993 compliant and suitable for implantation up to 90 days. It minimizes additive migration during processing, helping catheters retain smooth surfaces throughout their shelf life, while offering 15 color options for flexible and customized design. The low-migration Arothane™ ARP-B20 TPU is ISO 10993 compliant and suitable for implantation up to 90 days. It minimizes additive migration during processing, helping catheters retain smooth surfaces...

Zelluna ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Zelluna ASA (the " Company ") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the " Private Placement "), the allocation of 315,639 new shares in a retail offering via the PrimaryBid platform (the " PrimaryBidOffering "), and a potential subsequent repair offering of up to 800,000 new shares at the same subscription price as in the Private…

Zelluna ASA - Mandatory notification of trade

Reference is made to the private placement (the " Private Placement ") and the retail offering through PrimaryBid (the " PrimaryBid Offering ") announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR-forms related to (i) allocation of shares in the Private Placement; and (ii) share lending to facilitate settlement of tranche 1 of the Private Placement and the PrimaryBid Offering. Attachment 20251104 - PDMR attachment

Zelluna ASA - Successful private placement and retail offering

Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the pipelineStrong support from existing shareholders, management and board members with extensive life science and cell therapy experience.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S...

Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion…

Chronic Progressive Multiple Sclerosis Market Summary Chronic Progressive Multiple Sclerosis Market Summary Discover the chronic progressive multiple sclerosis new treatment @New Treatments for Chronic Progressive Multiple Sclerosis Key Factors Driving the Growth of the Chronic Progressive Multiple Sclerosis Market Rising Multiple Sclerosis Prevalence The global prevalence of multiple sclerosis is increasing, with earlier and more accurate diagnoses facilitated by...

Altri Comunicati